Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

ces with respect to the Company's clinical programs include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that preclinical data will indicate that urocortin 2 is not suitable for further clinical studies; risk that the CRF1 receptor antagonist candidate's Phase II proof of concept clinical studies will not support further clinical studies; and overall risk that the Company's clinical candidates will not proceed to later stage clinical trials. Risks associated with the Company's indiplon program include, but are not limited to, risk that indiplon approval and subsequent commercialization may be indefinitely delayed or never accomplished. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and report on Form 10Q for the quarter ended June 30, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

NEUROCRINE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(in thousands, except for per share data)

Three Months Ended Nine Months Ended

September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 ... trade association serving and representing the life sciences ... first Board of Directors meeting at The Foundry ... meeting of the organization brought together a broad ... region, and underscored the organization's early successes in ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
(Date:5/28/2015)... May 28, 2015 American Process ... (Oak Ridge, TN) recently signed a joint ... printing plastic resins using nanocellulose, a rapidly emerging ... 3D printing is the limited number of feedstock ... mechanical strength to printed parts for load bearing ...
(Date:5/27/2015)... , May 27, 2015 RXi ... company focused on discovering and developing innovative therapies ... today announced that it has commenced a public offering ... purchase shares of its common stock and overallotment ... stock. The shares of common stock, warrants and ...
Breaking Biology Technology:BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3
... , MONROVIA, Calif. and HANGZHOU, China, Nov. ... or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based ... children, today announced that the Company,s popular Gummy Bear products ... The Company has entered into a one year distribution contract ...
... CAMBRIDGE, Mass., Nov. 18 Knome, Inc., a ... announced the launch of KnomeDISCOVERY, the first fully ... for researchers. The new offering meets rapidly emerging ... that bundles affordable, research-tailored access to a broad ...
... , BOTHELL, Wash., Nov. 18 ... manufacturer, and marketer of proprietary cGMP hypothermic storage and cryopreservation ... it has been granted a Japanese patent for an application ... death caused by cold temperatures used in biopreservation. The patent ...
Cached Biology Technology:Niusule Expands Geographic Footprint in China 2Niusule Expands Geographic Footprint in China 3Knome Launches First Platform-Agnostic Human Genome Sequencing and Analysis Service for Researchers 2Knome Launches First Platform-Agnostic Human Genome Sequencing and Analysis Service for Researchers 3BioLife Solutions Granted Japanese Biopreservation Patent 2BioLife Solutions Granted Japanese Biopreservation Patent 3
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... , AMES, Iowa Wendy Wintersteen, dean of Iowa ... on Sunday of the importance of public-private partnerships in ... the American Association for the Advancement of Science in ... on research and development for sustainable agriculture and food ...
... our immune system can cause a state of chronic ... and result in disease. In the devastating disease multiple ... inflammation and degeneration of the brain. Researchers at BRIC, ... of regulatory blood cells that can combat such hyperactive ...
... findings on why skeletal muscle stem cells stop dividing ... unique therapeutic opportunity for managing muscle-wasting conditions in humans, ... According to CU-Boulder Professor Bradley Olwin, the loss ... can lead to sarcopenia, a debilitating muscle-wasting condition that ...
Cached Biology News:Iowa State University's Wintersteen talks partnerships at national science meeting 2New blood cells fight brain inflammation 2CU-Boulder stem cell research may point to new ways of mitigating muscle loss 2CU-Boulder stem cell research may point to new ways of mitigating muscle loss 3
...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
...
Biology Products: